Cancer Treatment Reviews
Volume 36, Issue 6 , Pages 485-491 , October 2010

Molecular biology of breast cancer stem cells: Potential clinical applications

  • Nam P. Nguyen

      Affiliations

    • Department of Radiation Oncology, University of Arizona, N. Campbell Ave, Tucson, AZ 85724-5081, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 520 694 7236; fax: +1 520 626 2032.
    • ,
  • Fabio S. Almeida

      Affiliations

    • Division of Nuclear Medicine, AZ, USA
    • ,
  • Alex Chi

      Affiliations

    • Department of Radiation Oncology, University of Arizona, N. Campbell Ave, Tucson, AZ 85724-5081, USA
    • ,
  • Ly M. Nguyen

      Affiliations

    • The School of Public Health, University of Michigan, Ann Arbor, MI, USA
    • ,
  • Deirdre Cohen

      Affiliations

    • Department of Radiation Oncology, University of Arizona, N. Campbell Ave, Tucson, AZ 85724-5081, USA
    • ,
  • Ulf Karlsson

      Affiliations

    • Department of Radiation Oncology, Marshfield Clinic, Marshfield, WI, USA
    • ,
  • Vincent Vinh-Hung

      Affiliations

    • Department of Radiation Oncology, University of Geneva, Geneva, Switzerland

Received 22 November 2009 ,Revised 7 February 2010 ,Accepted 13 February 2010.

References 

  1. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59:27–41
  2. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adj Exp Med Biol. 2009;608:1–22
  3. Early breast cancer trialist group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet. 1998;352:930–942
  4. Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780–783
  5. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100:672–679
  6. Seaberg RM, Van Der Kooy D. Stem and progenitor cells: the premature desertion of rigorous definitions. Trends Neurosci. 2003;26:125–131
  7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983–3988
  8. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821–5828
  9. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct side population of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004;101:14228–14233
  10. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007;67:4827–4833
  11. Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65:5506–5511
  12. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24− and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008;10:R10
  13. Liu R, Wang X, Chen G, et al. The prognostic role of a gene signature from tumorigenic breast cancer cell. N Engl J Med. 2007;356:217–226
  14. Bertucci F, Cervera N, Birnbaum D. A gene signature in breast cancer. N Engl J Med. 2007;356:1887–1888
  15. Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastases. Breast Cancer Res. 2006;8:R59
  16. Krohn A, Song YH, Muehberg F, Droll L, Beckmann C, Alt E. CXCR4 receptor positive spheroid forming cells are responsible for tumor invasion in vitro. Cancer Lett. 2009;280:65–71
  17. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555–567
  18. Morimoto K, Kim SJ, Tanei T, et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009;100:1062–1068
  19. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2010;16:45–55
  20. Tanei T, Morimoto K, Shimazu K, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy. Clin Cancer Res. 2009;15:4234–4241
  21. Restkova E, Reis-Filho JS, Jain RK, et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat. 2009;[e-publication]
  22. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of breast tumors. Nature. 2000;406:747–752
  23. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping, prognosis signatures. Breast Cancer Res. 2008;10:R65
  24. Hwang-Verslues WW, Kuo WH, Chang PH, et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS. 2009;4:e8377
  25. Honeth G, Bendahl PO, Ringner M, et al. The CD44+/CD24− phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10:R53
  26. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24− and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008;10:R10
  27. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Med. 2009;15:907–913
  28. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69:4116–4124
  29. Martinez-Estrada OM, Culleres A, Soriano FX, et al. The transcription factors Slug and Snail act as repressors of claudin-1 expression in epithelial cells. Biochem J. 2006;394:449–457
  30. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol. 1998;14:59–88
  31. Brennan RK, Brown AM. Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2004;9:119–131
  32. Katoh M. Wnt/Pcp pathway and human cancer. Oncol Rep. 2005;14:1583–1588
  33. Rattis FM, Voermans C, Reya T. Wnt signaling in the stem cell niche. Curr Opin Hematol. 2004;11:88–94
  34. Ling L, Nurcombe V, Cool SM. Wnt signaling controls the fate of mesenchymal stem cells. Gene. 2009;433:1–7
  35. Li X, Ren J. Isolation of CD24+/CD24−/low and side population cells from MDA-MB-453 cells and the analysis of their activation of Wnt and Notch pathway. Beijing Da Xue Xue Bao. 2008;40:471–475
  36. Vaillant F, Asselin-Labat ML, Shackelton M, Forrest NC, Lindeman JG, Visvader JE. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cell in mouse models of mammary tumorigenesis. Cancer Res. 2008;68:7711–7717
  37. Li Y, Welm B, Podsypanina K, et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA. 2003;26:15853–15858
  38. Cohen MM. The Hedgehog signaling network. Am J Med Genet. 2003;123A:5–28
  39. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary cells. Cancer Res. 2006;66:6063–6071
  40. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11:259–273
  41. Tanaka H, Nakamura M, Kameda C, et al. The Hedgehog signaling pathway plats an essential role in maintaining the CD44+ CD24−/low subpopulation and the side population of breast cancer cells. Anticancer Res. 2009;29:2147–2157
  42. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–776
  43. Koch U, Radkte F. Notch and cancer: double edged sword. Cell Mol Life Sci. 2007;64:2746–2762
  44. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene. 2008;27:5124–5131
  45. Farnie G, Clarke RB. Mammary cancer and breast cancer – role of Notch signaling. Stem Cell Rev. 2007;3:169–175
  46. Guo X, Wang XF. Signaling cross-talk between TGF beta/GMP and other pathways. Cell Res. 2009;19:71–88
  47. Hayward P, Kalmar T, Arias AF. Wnt/Notch signaling and information processing during development. Development. 2008;135:411–424
  48. Teissedre B, Pinderhughes A, Incassati A, Hatsell HJ, Hiremath M, Cowin B. MMTV-Wnt1 and −ΔN89β-Catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumors. PLoS. 2009;4:e4537
  49. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline. Eur J Cancer. 2009;45:228–247
  50. Dave B, Chang J. Treatment resistance in stem cells and breast cancer. J Mammary Gland Biol Neoplasia. 2009;14:79–82
  51. Tacca O, LeHeurteur M, Durando X, et al. Metastatic cancer: overall survival related to successive chemotherapies. What do we gain after the third line. Cancer Invest. 2009;27:81–85
  52. Shafee N, Smith CR, Wei S, et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 2008;68:3243–3250
  53. Li HZ, Yi TB, Wu ZY. Suspension culture combined with chemotherapy agents for sorting of breast cancer stem cells. BMC Cancer. 2008;8:135
  54. Staud F, Pavek P. Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol. 2005;37:720–725
  55. Johnson A. The timing of treatment in breast cancer: gaps and delays in treatment can be harmful. Breast Cancer Res Treat. 2000;60:201–209
  56. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA. 2007;104:618–623
  57. Chen MS, Woodward WA, Behbod F, Peddibhotia S, Alfaro MP. Wnt/β-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci. 2006;120:468–477
  58. Ogura A, Watanabe Y, Iizuka D, et al. Radiation-induced apoptosis of tumor cells is facilitated by inhibition of the interaction between survivin and Smac/DIABLO. Cancer Lett. 2008;259:71–81
  59. Rodel F, Frey B, Leitmann W, Capalbo G, Weiss C, Rodel C. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and a murine xenograft model. Int J Radiat Oncol Biol Phys. 2008;71:247–255
  60. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112:533–543
  61. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105:4163–4169
  62. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y. NF-κB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat. 2008;111:419–427
  63. Liu Y, Lu WL, Guo J, et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes. J Contr Rel. 2008;129:18–25
  64. Sweeney CJ, Mehrotra S, Sadaria MR, et al. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastases and improves survival in a xenograft model of breast cancer. Mol Cancer Ther. 2005;4:1004–1012
  65. Guo ZS, Thorne SH, Barlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta. 2008;1785:217–231
  66. Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PW. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther. 2007;15:1522–1530
  67. Marcato P, Dean CA, Giacomantonio CA, Lee PWK. Oncolytic reovirus effectively targets breast cancer stem cells. Mol Ther. 2009;17:572–579
  68. Eriksson M, Guse K, Bauerschmitz G, et al. Oncolytic adenoviruses kill breast cancer initiating CD44+CD24−/low cells. Mol Ther. 2007;15:2088–2093
  69. Kimata H, Imai T, Kikumori T, et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol. 2006;13:1078–1084
  70. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:1–5
  71. Anisimov VN, Egormin PA, Piskunova TS, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle. 2010;9:188–197
  72. Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8:2031–2040
  73. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27:3297–3302
  74. Biron P, Durand M, Roche H, et al. Pegase 3: a prospective randomized trial of FEC with or without high dose thiotepa, cyclophosphamide and autologous stem cell transplantation as first line treatment of metastatic breast cancer. Bone Marrow Transplant. 2008;41:555–562
  75. Vredenburgh JJ, Madan B, Coniglio D, et al. A randomized phase III trial of immediate consolidation with high dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant. 2006;37:1009–1015
  76. Tokuda Y, Tajima T, Narabayashi M, et al. Phase III study to evaluate the use of high dose chemotherapy as consolidation of treatment for high risk postoperative breast cancer: Japan clinical group study, JCOG 9208. Cancer Sci. 2008;99:145–151
  77. Farquhar CM, Marjoribanks J, Lethaby A, Basser R. High dose chemotherapy for poor prognosis breast cancer: systemic review and meta-analysis. Cancer Treat Rev. 2007;33:325–337
  78. Croker AK, Goodale D, Chu J, et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2008;[e-publication]
  79. Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, Gianni AM. Induction of cyclophosphamide resistance by aldehyde dehydrogenase transfer. Blood. 1996;87:1097–1103
  80. Tsukamoto N, Chen J, Yoshida A. Enhanced expressions of glucose-6-phosphate dehydrogenase and elevation of reduced glutathione level in cyclophosphamide resistant human leukemic cells. Blood Cells Mol Dis. 1998;24:231–238
  81. Murphy JJ, Heptinstall S, Mitchell RJ. Randomized double-bind placebo controlled trial of feverfew in migraine prevention. Lancet. 1988;2:189–192
  82. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache. 2004;44:885–890
  83. Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutr. 2000;3:509–514
  84. Curry EA, Murry DJ, Yoder C, et al. Phase I dose escalation trial of feverfew with standardized dose of parthenolide in patients with cancer. Invest New Drugs. 2004;22:299–305
  85. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science. 1988;282:1332–1334
  86. Vidal L, Pandha HS, Yap TA, et al. A phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer. Clin Cancer Res. 2008;14:7127–7137
  87. Laurie SA, Bell JC, Atkins HL, et al. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res. 2006;12:2555–2562
  88. Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic pox virus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008;9:533–542
  89. Sibley G, Jamieson TA, Marks LB, Anscher MS, Prosnitz LR. Radiotherapy alone for medically inoperable stage I non-small cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys. 1998;40:149–154
  90. Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small lung cancer. Int J Radiat Oncol Biol Phys. 2006;66:117–125
  91. Nguyen NP, Garland L, Welsh J, Hamilton R, Cohen D, Vinh-Hung V. Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung cancer. Cancer Treat Rev. 2008;34:719–727
  92. Vredenburgh JJ, Madan B, Coniglio D, et al. A randomized phase III comparative trial of immediate consolidation with high dose hemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant. 2006;37:1009–1015
  93. Cachin F, Prince HM, Hogg A, Ware RE, Hicks RJ. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high dose chemotherapy. J Clin Oncol. 2006;24:3026–3031
  94. Schwarz-Dose J, Untch M, Tiling R, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009;27:535–541
  95. Berriolo-Riedinger A, Touzery C, Riedinger JM, et al. [18F]FDG–PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34:1915–1924
  96. Park HC, Chang JY, Hahm ER, Park S, Kim HK, Yang CH. Quercetin, a potent inhibitor against β-catenin/Tcf signaling in SW-480 colon cancer cells. Biochem Biophys Res Commun. 2005;328:227–234
  97. Takahashi-Yanaga F, Sasaguri T. Drug development targeting the glycogen synthase kinase-3β mediated signal transduction pathway: inhibitors of the Wnt/β-catenin signaling pathway as a novel anticancer drugs. J Pharmacol Sci. 2009;109:179–183
  98. McAnulty SR, McAnulty LS, Nieman DC, et al. Chronic quercetin ingestion and exercise induced oxidative damage and inflammation. Appl Physiol Nutr Metab. 2008;33:254–262
  99. Zell JA, Pelot D, Chen WP, Mc Laren CE, Gerner EW, Meyskens FL. Risks of cardiovascular events in a randomized placebo-controlled, double blind trial of difluoromethyllornithine plus sulindac for the prevention of sporadic colorectal adenoma. Cancer Prev Res. 2009;2:209–212
  100. Osipo C, Patel P, Pizzo P, et al. ErbB-2 inhibition activate Notch 1 and sensitizes breast cancer cells to a γ-secretase inhibitor. Oncogene. 2008;27:5019–5032
  101. Mecocci P, Bladstrom A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer disease: post hoc analysis of ADAS-cog and SIB total and single item scores from six randomized, double bind, placebo controlled studies. Int J Geriatr Surg. 2009;24:532–538
  102. Zhang X, Harrington N, Moraes RC, Wu MF, Hilsenbeck SG, Lewis MT. Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened. Breast Cancer Res. 2008;115:505–521

PII: S0305-7372(10)00037-X

doi: 10.1016/j.ctrv.2010.02.016

Cancer Treatment Reviews
Volume 36, Issue 6 , Pages 485-491 , October 2010

Article Tools